Dr. Reddy's Laboratories Limited RDY
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 3.95% | -16.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.95% | -16.14% | |||
| Cost of Revenue | 0.76% | -0.21% | |||
| Gross Profit | 7.87% | -29.92% | |||
| SG&A Expenses | 0.50% | 0.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 33.37% | -14.17% | |||
| Total Operating Expenses | 1.09% | -1.21% | |||
| Operating Income | 186.58% | -92.13% | |||
| Income Before Tax | 168.68% | -87.44% | |||
| Income Tax Expenses | 632.88% | -105.90% | |||
| Earnings from Continuing Operations | 90.89% | -81.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 2,206.41% | -101.93% | |||
| Net Income | 95.06% | -82.29% | |||
| EBIT | 186.58% | -92.13% | |||
| EBITDA | 69.32% | -74.93% | |||
| EPS Basic | 94.81% | -82.28% | |||
| Normalized Basic EPS | 125.50% | -88.84% | |||
| EPS Diluted | 94.81% | -82.27% | |||
| Normalized Diluted EPS | 125.50% | -88.83% | |||
| Average Basic Shares Outstanding | -0.01% | 0.13% | |||
| Average Diluted Shares Outstanding | -0.01% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||